Peer

Clinical predictors and electrodiagnostic characteristics in patients with Guillain-Barré syndrome with respiratory failure: a retrospective, matched case-control study

Kanchana Charoentanyarak¹, Apiradee Singjam¹ and Jittima Saengsuwan²

¹ Rehabilitation Medicine Unit, Khon Kaen Hospital, Khon Kaen, Thailand

² Department of Rehabilitation Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

ABSTRACT

Background. Respiratory failure is a common complication of Guillain-Barré syndrome (GBS). This study aimed to determine the clinical predictors and electrodiagnostic (EDx) characteristics in patients with Guillain-Barré syndrome (GBS) with respiratory failure.

Methods. The retrospective study included 29 confirmed GBS cases with respiratory failure and age- (\pm 5 years) and sex-matched controls (1:1). The dependent *t*-test and McNemar–Bowker test were used to analyse the continuous and categorical data, respectively. In addition, a multiple logistic regression analysis was used to analyse the predictive factors for respiratory failure.

Results. Among both cases and controls, the majority were male (72.4%), and the average age was 50.9 years. The data showed that patients with respiratory failure had higher GBS disability scores, lower motor power (\leq 3) of the hip flexors and ankle dorsiflexors, and experienced facial and bulbar palsy. In the multivariate analysis, the significant predictive factors were bulbar palsy (AOR 10.4 [95% CI [2.6–41.4]) and motor power of hip flexors \leq 3 (AOR 31.4 [95% CI [3.1–314.5]). Patients with respiratory failure had lower compound muscle action potential amplitude of the ulnar and tibial nerves. The median, ulnar, and tibial nerve conduction studies were more likely to reflect inexcitability. The GBS subtypes in GBS patients with and without respiratory failure were not significantly different.

Conclusions. Bulbar palsy and motor power of the hip flexors ≤ 3 were significant predictors for respiratory failure. The GBS subtypes in patients with and without respiratory failure were not significantly different.

Subjects Epidemiology, Neurology, Respiratory Medicine

Keywords Association, Case-control, Electrodiagnostic study, Guillain-Barré syndrome, Mechanical ventilator

INTRODUCTION

Guillain-Barré syndrome (GBS) is an immune-mediated neurological condition characterised by acute or sub-acute progressive symmetric bilateral muscular weakness and

Submitted 30 September 2021 Accepted 21 January 2022 Published 10 February 2022

Corresponding author Jittima Saengsuwan, sjittima@kku.ac.th

Academic editor Jafri Abdullah

Additional Information and Declarations can be found on page 9

DOI 10.7717/peerj.12930

© Copyright 2022 Charoentanyarak et al.

Distributed under Creative Commons CC-BY 4.0

OPEN ACCESS

areflexia (*Hughes & Cornblath*, 2005). The worldwide incidence of GBS is approximately 1.1–1.8 cases per 100000 (*McGrogan et al.*, 2009). Incidence increases with age and is higher in men (*Sejvar et al.*, 2011; *Kasemsap et al.*, 2021). Respiratory failure is a common complication of GBS, caused by respiratory muscle weakness and impaired secretion clearance (*Green, Baker & Subramaniam*, 2018). The prevalence of respiratory failure in GBS ranges from 13.0–50.9% (*Malaga et al.*, 2021; *Shangab & Al Kaylani*, 2021; *Sharshar et al.*, 2003; *Sudulagunta et al.*, 2015; *Toamad et al.*, 2015; *Umer et al.*, 2019; *Ning et al.*, 2020). According to a recent meta-analysis, the clinical risk factors for respiratory failure in patients with GBS are a short time from symptom onset to hospital admission, bulbar or neck weakness, and severe muscle weakness on admission (*Green, Baker & Subramaniam*, 2018).

GBS has several subtypes with distinct clinical, pathological, and electrophysiological features, namely: acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute motor-sensory axonal neuropathy (AMSAN), and Miller Fisher syndrome (*Hughes & Cornblath, 2005; McGrogan et al., 2009*). An electrodiagnostic (EDx) study is the cornerstone for diagnosing GBS subtypes and helps understand the pathophysiology and assess the prognosis of GBS (*Uncini & Kuwabara, 2018*). In Western countries, the most common subtype, which accounts for approximately 55–80% of cases, was AIDP (*Doets et al., 2018*). By comparison, in Asian countries, the proportion of AIDP ranged lower (40–54%), and the axonal type was up to 66.7% (*Areeyapinan & Phanthumchinda, 2010; Ye et al., 2010; Verma et al., 2013; Doets et al., 2018*).

Studies of EDx characteristics and predictors for GBS with respiratory failure are limited. For example, *Durand et al. (2006)* found that demyelinating GBS was more common in patients who were mechanically ventilated (MV) (85% *vs.* 51%) in France (*Durand et al., 2006*). In contrast, a univariate analysis from a prospective study in Bangladesh showed that the presentation of an axonal variant was a significant risk factor for MV (*Islam et al., 2019*). Since the proportion of GBS subtypes is different in Western and Asian countries, the characteristics of GBS with respiratory failure may be different. Thus, the aim of this study was to 1) determine clinical predictors in patients with GBS with respiratory failure; 2) examine the difference in EDx characteristic in patients with GBS with respiratory failure; and, 3) determine whether there were differences in GBS subtypes among patients with and without respiratory failure.

MATERIALS & METHODS

A retrospective matched case-control study was conducted at Khon Kaen Hospital, Thailand, between March 2020 and March 2021. The study was reviewed and approved by the Khon Kaen Hospital Ethics Committee for Human Research (KEXP63008), performed according to the ethical principles described in the Declaration of Helsinki, and all methods were performed following the relevant guidelines and regulations. The study population included patients who underwent an electrodiagnostic (EDx) study between January 2013 and December 2019. We designed the study to have 1:1 matching. The matching criteria were age in years (\pm 5 years) and sex. The inclusion criteria were age \geq 18 years, underwent EDx study, and diagnosed with GBS. The exclusion criteria were pure Miller Fisher syndrome, another diagnosis (*i.e.*, diabetic polyneuropathy, myopathy), or incomplete history record.

The data recorded included date of onset, clinical symptoms, discharge date, and GBS disability score (*Hughes et al., 1978*) on admission. EDx studies were performed by board-certified rehabilitation physicians using the Nicolet Biomedical Viking quest system (Nicolet Biomedical, Madison, WI, USA). GBS was diagnosed by the criteria proposed by Rajabally et al., which includes the following classifications: acute inflammatory demyelinating polyradiculoneuropathy (AIDP), axonal GBS, equivocal, and normal. Axonal GBS is further subclassified to acute motor axonal neuropathy (AMAN), acute motor-sensory axonal neuropathy (AMSAN), and inexcitable (*Rajabally et al., 2015*; *Uncini & Kuwabara, 2018*). A detailed description of the criteria is in the supplementary material. Sural sparing was defined by a greater decrease in the median and or ulnar SNAP compared to the decrease in sural SNAP (*Umapathi et al., 2015*). Respiratory failure was defined as a need for invasive MV within 30 days after admission (*Sharshar et al., 2003*).

Sample size calculation

The sample size calculation was based on a previous study which found that patients with AIDP subtypes comprise 85% of ventilator patients and 51% of non-ventilator patients (34% difference). The study was designed to achieve an 80% power for detecting differences with a 2-sided type I error of 5% (*Durand et al., 2006*) with a two-sided type I error of 5%. According to these criteria, the estimated sample size was 58 patients (29 per arm).

Statistical analysis

Continuous data were presented as means and standard deviations. Categorical data were presented as frequencies and percentages. A dependent *t*-test was used to compare the continuous paired data, and the student's *t*-test was used to compare the continuous data from the sensory SNAP, which cannot be paired because there were multiple instances of no electrical response data. As for nerve conduction parameters, when data was available from both the left and right, the data were randomised to select one side from each individual. McNemar's test was used to compare the paired data, while the Chi-square test was used for non-matched comparisons of proportions. When the *p*-value was <0.2, these variables were included in the univariate analysis. Multivariate logistic regression models were used to analyse predictive factors for GBS with respiratory failure. Adjusted odds ratios (AOR) with 95% confidence intervals (CI) were calculated, and values of *p* < 0.05 were considered significant. Statistical analyses were performed using Stata version 13.1 (Stata Statistical Software: Release 13. College Station, TX: StataCorp LP.).

RESULTS

Fifty-eight patients diagnosed with GBS were enrolled, of whom 42 (72.4%) were male. The male-to-female ratio was 2.6:1. The respective mean age was 51.2 and 50.6 in GBS patients with and without respiratory failure. The emergence of cases was more common

Variables	Respiratory failure (<i>n</i> = 29)	No respiratory failure $(n = 29)$	P value
Age (years; mean (SD))	51.2 (15.5)	50.6 (15.1)	Matching criteria
Sex, Male/Female	21 (72.4)/8 (27.6)	21 (72.4)/8 (27.6)	Matching criteria
Smoking	11 (37.9)	12 (41.4)	1.0
Alcoholic drinking	12 (41.4)	14 (48.3)	0.77
Comorbidity			NA
HIV	1 (3.4)	1 (3.4)	1.0
Diabetes mellitus	5 (17.2)	4 (13.8)	1.0
Hypertension	11 (37.9)	4 (13.8)	0.07
Dyslipidemia	3 (10.3)	1 (3.4)	0.61
Autoimmune	1 (3.4)	2 (6.9)	1.0
Hepatitis B	1 (3.4)	3 (10.3)	0.61
Season			0.64
Summer	5 (18.5)	7 (24.1)	
Rainy	13 (48.1)	12 (41.4)	
Winter	9 (31.0)	10 (34.5)	
Antecedent event			
Diarrhea	4 (13.8)	4 (13.8)	1.0
URI symptoms	1 (3.4)	8 (27.6)	0.15
After vaccination	1 (3.4)	0 (0)	1.0
Fever	7 (24.1)	6 (20.7)	1.0

Table 1 Demographic data of participants (n = 58).

Notes.

Data are presented in n (%) unless otherwise specified.

in the winter and rainy seasons compared to summer. The three most common antecedent events were fever (22.4%), upper respiratory tract infection (15.5%), and diarrhea (13.8%) (Table 1).

All patients had lower limb weakness (100.0%), and most had numbness (69.0%). Patients with respiratory failure had lower motor power in both the upper and lower extremities and were more likely to have facial or bulbar palsy. The GBS disability score was higher in the respiratory failure group (Table 2). The univariate analysis showed the following were associated with respiratory failure: facial palsy (OR 4.5 [95% CI [1.4–13.7]]), bulbar palsy (OR 7.0 [95% CI [2.2–22.2]]), motor power \leq 3 in hip flexors (OR 19.8 [95% CI [2.4–165.8]]), and ankle dorsiflexors (OR 3.4 [95% CI [1.0–11.4]]) together with GBS disability scale \geq 4 (OR 17.1 [95% CI [2.0–144.1]]). In the multivariate analysis, the significant predictive factors were bulbar palsy (AOR 10.4 [95% CI [2.6–41.4]]) and motor power of hip flexors \leq 3 (AOR 31.4 [95% CI [3.1–314.5]]) (Table 3).

An EDx study was done within seven days in a respective 51.7% and 37.9% of patients with and without respiratory failure (p = 0.051). Overall, the most common inexcitable motor nerve was the peroneal nerve (51.0%), and the most common inexcitable sensory nerve was the median nerve (66.2%). The median motor, ulnar motor, ulnar sensory, and tibial nerves were more likely to be inexcitable in patients with respiratory failure. The CMAP amplitude of the ulnar and tibial nerves was smaller in patients with respiratory

0 / 1	1 /	· · · ·		
Clinical signs and symptoms	Respiratory failure (n = 29)	Controls $(n=29)$	Mean difference (95% CI)	P value
Symptom duration before admission (days), mean (SD)	5.5 (4.0)	7.9 (5.1)	-2.4 (-4.8 to 0.0)	0.051
Symptom duration before admission \leq 7 days	24 (82.8)	20 (69.0)	NA	0.22
Motor power on admission, mean (SD)				
Shoulder abductors	2.8 (1.4)	3.6 (1.0)	-0.9 (-1.6 to 0.1)	0.020
Wrist extensors	2.8 (1.5)	3.8 (1.2)	-1.0 (-1.8 to 0.3)	0.009
Hip flexors	1.7 (1.1)	3.2 (0.8)	-1.5 (-2.0 to 1.0)	< 0.001
Ankle dorsiflexors	2.0 (1.3)	3.4 (1.0)	-1.4 (-1.9 to 0.9)	< 0.001
Motor power on admission grade ≤ 3				
Shoulder abductors	17 (58.6)	12 (41.4)	NA	0.19
Wrist extensors	17 (58.6)	12 (41.4)	NA	0.19
Hip flexors	28 (96.6)	17 (58.6)	NA	0.001
Ankle dorsiflexors	24 (82.8)	17 (58.6)	NA	0.043
Impair or absent pinprick sensation	19 (65.5)	21 (72.4)	NA	0.26
Facial palsy	17 (58.6)	7 (24.1)	NA	0.013
Bulbar palsy	22 (69.0)	9 (31.0)	NA	0.007
Oculoplegia	5 (17.2)	1 (3.4)	NA	0.13
Autonomic dysfunction	5 (17.2)	2 (6.9)	NA	0.38
Hyporeflexia or areflexia of UE	29 (100)	25 (86.2)	NA	0.41
Hyporeflexia or areflexia of LE	29 (100)	27 (93.1)	NA	0.57
GBS Disability score on admission, mean (SD)	4.4 (0.6)	3.5 (0.7)	0.9 (0.5 to 1.2)	< 0.001
GBS Disability score on admission ≥ 3	28 (96.6)	18 (62.1)	NA	0.001
CSF hyperalbuminemia	24 (82.8)	22 (75.9)	NA	0.73

Table 2 Clinical signs and symptoms in GBS with and without respiratory failure (n = 58).

Notes.

Abbreviations: GBS, Guillain-Barré syndrome; UE, upper extremities; LE, lower extremities; SD, standard deviation. Data are presented in n (%) unless otherwise specified.

GBS.				
	Unadjusted		Adjusted	
	OR (95% CI)	P value	OR (95% CI)	P value
Duration of symptoms \leq 7 days	2.2 (0.6–7.5)	0.23		
Shoulder abductors gr ≤ 3	2.0 (0.7-5.7)	0.19		
Wrist extensors gr ≤ 3	2.0 (0.7-5.7)	0.19		
Hip flexors gr ≤ 3	19.8 (2.4–165.8)	0.006	31.4 (3.1–314.5)	0.003
Ankle dorsiflexors gr ≤ 3	3.4 (1.0–11.4)	0.049		
Bulbar palsy	7.0 (2.2–22.2)	0.001	10.4 (2.6–41.4)	0.001
Facial palsy	4.5 (1.4–13.7)	0.009		
GBS disability score on admission ≥ 4	17.1 (2.0–144.1)	0.009		

Table 3 Unadjusted and adjusted odds ratio between different variables and respiratory failure in CPC

Notes.

Abbreviations: GBS, Guillain-Barré syndrome; OR, odds ratio; CI, confidence interval.

failure. Both groups showed a similar percentage of the sural sparing pattern (25% vs.

Table 4 Electrodiagnostic results in GBS with and without respiratory failure.

Electrodiagnostic results	Respiratory failure (<i>n</i> = 29)	Controls $(n = 29)$	Mean difference (95% CI)	P valu
Duration from onset to EDx study (days)	7.0 (5.5–13.5)	8.0 (4.0–9.5)	NA	0.079
$EDx \leq 7 \text{ days, } n (\%)$	15 (51.7)	11 (37.9)	NA	0.51
Motor Median NCS $(n = 15)$				
Latency (ms)	9.4 (5.2)	6.7 (3.5)	2.7 (-1.1 to 6.5)	0.15
NCV (m/s)	44.2 (10.6)	45.3 (13.0)	-1.1 (-8.4 to 6.2)	0.75
CMAP (mV)	2.0 (2.1)	3.3 (3.1)	-1.4 (-3.4 to 0.7)	0.17
No response, n/total n (%)*	15/33 (45.5)	5/44 (11.4)	NA	0.001
Motor Ulnar nerve $(n = 20)$				
Latency (ms)	5.1 (2.0)	3.7 (1.7)	1.4 (-0.01 to 2.8)	0.052
NCV (m/s)	46.2 (12.9)	54.2 (9.3)	-8.0 (-15.9 to -0.1)	0.048
CMAP (mV)	1.9 (1.6)	3.8 (2.5)	-1.9 (-3.4 to -0.4)	0.015
No response, n/total n (%) [*]	9/33 (27.3)	2/45 (4.4)	NA	0.004
Motor Peroneal nerve $(n = 8)$				
Latency (ms)	7.2 (2.0)	6.1 (3.2)	1.0(-2.1 to 4.1)	0.47
NCV (m/s)	33.5 (15.1)	43.9 (8.3)	-10.4 (-24.7 to 3.8)	0.13
CMAP (mV)	1.2 (0.9)	1.9 (1.2)	-1.8 (-2.0 to 0.5)	0.21
No response, n/total n (%) [*]	30/50 (60.0)	21/50 (42.0)	NA	0.072
Motor Tibial nerve $(n = 20)$				
Latency (ms)	7.7 (2.9)	5.0 (2.7)	2.7 (0.8 to 4.5)	0.008
NCV (m/s)	35.4 (12.3)	38.9 (10.1)	-3.5 (-10.7 to 3.7)	0.32
CMAP (mV)	1.5 (1.5)	4.3 (3.4)	-2.7 (-4.6 to -0.9)	0.006
No response, n/total n (%)*	13/51 (25.5)	5/50 (10.0)	NA	0.042
Sensory Median nerve				
SNAP $(\mu V)^a$ $(n=9)$	21.5(13.9)(n=6)	17.3 (7.5) $(n = 12)$	4.2 (-6.3 to 14.7)	0.51
No response, n/total n (%) [*]	21/28 (75.0)	24/40 (60.0)	NA	0.198
Sensory Ulnar nerve				
SNAP $(\mu V)^a$	17.8 (8.6) $(n=6)$	14.3 (8.7) $(n = 19)$	3.5 (-4.9 to 11.9)	0.40
No response, n/total n (%) [*]	22/29 (75.9)	15/40 (37.5)	NA	0.002
Sensory Sural nerve				
SNAP $(\mu V)^a$	18.0(6.4)(n=10)	12.0 (6.8) $(n = 12)$	6.0 (-0.1 to 11.9)	0.047
No response, n/total n (%) [*]	30/45 (66.7)	26/45 (57.8)	NA	0.38
Sural sparing, n/total n (%)	7/28 (25%)	6/28 (21.4%)	NA	1.00
Needle EMG study				
Axonal denervation, n/total n (%)*	9/25 (36.0)	6/24 (25.0)	NA	0.40

Notes.

Abbreviations: CMAP, compound muscle action potential; NCV, nerve conduction velocity; EMG, electromyography; NA, not applicable; SNAP, sensory nerve action potential.

The data were analysed by dependent *t*-test unless otherwise specified.

^aStudent's *t*-test.

Data are presented in mean (SD) unless otherwise specified.

21.4%) (Table 4). Axonal GBS predominated in both groups (48.3%), and no difference was found in the proportion of axonal and demyelinating GBS (Table 5).

^{*}Chi-square test.

GBS subtypes	Respiratory failure $(n = 29)$	Controls $(n=29)$	P value
AIDP	10 (34.5)	10 (34.5)	0.67
Axonal GBS	14 (48.3)	14 (48.3)	
AMAN	7 (24.1)	6 (20.7)	
AMSAN	7 (24.1)	7 (24.1)	
Inexcitable	0 (0.0)	1 (3.4)	
Equivocal	4 (13.8)	1 (3.4)	
Normal	1 (3.4)	4 (13.8)	

 Table 5
 GBS classification in GBS with and without respiratory failure.

Notes.

Abbreviations: GBS, Guillain-Barré syndrome; AIDP, Acute inflammatory demyelinating polyradiculoneuropathy; AMAN, acute motor axonal neuropathy; AMSAN, acute motor sensory axonal neuropathy. Data are presented in n (%).

DISCUSSION

Compared to previous epidemiological studies in Thailand, our patients with respiratory failure were older (50.6 vs. 42.0–43.0 years), which correlates to previous findings in which the mortality rate in the older age group was higher than the younger age group (5.2% in patients age > 65 years compared to 1.5% and 3.6% in patients age > 18 and 19-64years, respectively) (Areeyapinan & Phanthumchinda, 2010; Kasemsap et al., 2021; Wen et al., 2021). Similarly, Shangab & Al Kaylani (2021) reported that older age at presentation is a major predictor for the need for mechanical ventilation (MV). Additionally, we found a higher male-to-female ratio of 2.6:1 compared to 1.6:1 in overall GBS, suggesting that males might have a higher morbidity than females (*Kasemsap et al., 2021*). This observation is different from a meta-analysis that revealed that men were no more likely to require MV (Green, Baker & Subramaniam, 2018) but was consistent with previous studies in Bangladesh and the United Arab Emirates, which showed that 68-78% of ventilated patients were male (Shangab & Kaylani, 2021; Islam et al., 2019). The seasonal prevalence of GBS was comparable to previous studies confirming that the rainy and winter seasons had significantly more patients (Areeyapinan & Phanthumchinda, 2010; Kasemsap et al., 2021).

The following factors are related to respiratory failure: rapid disease progression, weakness of respiratory muscles, lower Medical Research Council (MRC) score at nadir, a short time from symptom onset to hospital admission, facial palsy, neck weakness, bilateral facial weakness, autonomic dysfunction, and bulbar palsy (*Lawn et al., 2001*; *Durand et al., 2006*; *Green, Baker & Subramaniam, 2018*; *Wen et al., 2021*). Our univariate analysis revealed significant factors: weakness in the hip flexors and ankle dorsiflexors, higher GBS disability score on admission, bulbar palsy and facial palsy. However, the multivariate analysis showed that the only significant predictors were bulbar palsy (AOR 10.4) and weakness of hip flexors of MRC ≤ 3 (AOR 31.4). By comparison, bulbar weakness was a significant predictor of respiratory failure in several studies (*Malaga et al., 2021*; *Kanikannan et al., 2014*; *Toamad et al., 2015*; *Wu et al., 2015*; *Green, Baker & Subramaniam, 2018*; *Islam et al., 2019*; *Umer et al., 2019*; *Luo et al., 2020*; *Ning et al., 2020*).

Although the short time from symptom onset to admission (\leq 7 days) was a significant predictor in several studies (*Rantala et al., 1995; Toamad et al., 2015; Wu et al., 2015; Green, Baker & Subramaniam, 2018; Umer et al., 2019; Luo et al., 2020*), it did not reach statistical significance in our univariate and multivariate analyses. This may be because our hospital is a tertiary hospital, and some patients were referred from community hospitals, so our hospital admission date may not be the date of initial hospital admission. Our study showed that hip flexors weakness \leq 3 was a strong predictor for respiratory failure, which agrees with *Walgaard et al. (2010)* and *Wu et al. (2015)* who showed that lower muscle power was a risk factor for MV. In a recent meta-analysis, increased risk of intubation was associated with a short time from symptom onset to hospital admission. Facial weakness and autonomic dysfunction were not significant predictors after multivariable analysis (*Green, Baker & Subramaniam, 2018*).

The findings of lower CMAP amplitude and inexcitable motor nerve conduction agree with *Sundar et al. (2005)* who found markedly attenuated compound muscle action potentials and inexcitable motor nerves were more common in the ventilated group, and *Walgaard et al. (2010)* who showed that patients with unexcitable nerves on nerve conduction study had a greater chance of requiring prolonged MV. However, we did not investigate the role of EDx features as predictive factors because the results of the matched data were not complete leading to a small sample size among groups.

A sural sparing pattern was found in 25% of mechanically ventilated patients and 21.4% in those who were not. Our results agree with those of *Rasera et al.* (2021) who found a sural sparing pattern in 21% of patients with GBS in Italy, somewhat higher than the respective 15% and 16.7%% reported by *Sharma et al.* (2016) in India and *Gómez-Piña et al.* (2021) in Mexico (16.7%). Notwithstanding, these findings are lower than previous studies where the sural sparing pattern in GBS patients ranged between 34.4 and 72% (*Al-Shekhlee, Robinson & Katirji, 2007; Derksen et al., 2014; Ahdab et al., 2018*). The distribution of GBS subtypes may play a role, as we found a higher occurrence of axonal subtypes than other studies where the sural sparing pattern was more common in AIDP (*Yadegari, Nafissi & Kazemi, 2014; Sharma et al., 2016; Gómez-Piña et al., 2021; Mani et al., 2021*). In addition, the difference in findings may be related to the timing of Edx since previous studies demonstrated an increase in the sural sparing pattern with serial EDx (*Gupta et al., 2008; Umapathi et al., 2015*).

Regarding EDx results, we found no difference in GBS subtypes in the group with respiratory failure, which is consistent with some studies (*Green, Baker & Subramaniam*, 2018; *Parveen et al.*, 2020) but contradicts others where a higher proportion of demyelinating (*Durand et al.*, 2006; *Yamagishi et al.*, 2017) or axonal GBS subtypes was found (*Shangab & Al Kaylani*, 2021; *Walgaard et al.*, 2010; *Islam et al.*, 2019; *Luo et al.*, 2020).

We examined the predictive factors for respiratory failure in patients with GBS using a case-control study design, which is useful when investigating uncommon diseases. Since age and sex were matching criteria, we could not establish the role of these variables as potential predictors, although we found that older age and men seemed to more commonly

have respiratory failure. Another limitation of case-control studies is the inability to show the temporal relationship between factors and outcomes because cases and controls are investigated after the diagnosis. Since our study employed previously recorded data, some missed factors might have been potential risk/predictive factors associated with respiratory failure in GBS (*i.e.*, neck flexor weakness) (*Umer et al.*, 2019) or parameters of pulmonary function (*i.e.*, vital capacity) (*Sharshar et al.*, 2003; *Durand et al.*, 2006; *Kanikannan et al.*, 2014). Additionally, although a serial EDx study was not done, if it were, it might lead to a change in the EDx due to a resolution of reversible conduction failure or misclassification of subtypes (*Uncini et al.*, 2017; *Leonhard et al.*, 2019; *Mani et al.*, 2021). The generalizability of data may be limited because it was a single-centre source. Moreover, we had small samples for each EDx parameter limiting the ability to integrate EDx results in the multivariate analysis. The main limitation was the lack of a temporal relationship between the clinical/electrodiagnostic features of GBS and respiratory failure, pointing out the need for a well-designed prospective study.

CONCLUSION

Bulbar palsy and motor power of the hip flexors \leq 3 were significant predictors for respiratory failure. No significant difference in GBS subtypes was found in patients with and without respiratory failure.

ACKNOWLEDGEMENTS

The authors thank Mr. Bryan Roderick Hamman under the aegis of the Publication Clinic KKU, Thailand, for assistance with the English-language presentation.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

The authors received no funding for this work.

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Kanchana Charoentanyarak conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Apiradee Singjam conceived and designed the experiments, performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
- Jittima Saengsuwan conceived and designed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.

Data Availability

The following information was supplied regarding data availability: The raw data are available in the Supplemental File.

Supplemental Information

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.12930#supplemental-information.

REFERENCES

- Ahdab R, Noureldine MHA, Mohammedi K, Nader M, Zouari HG, Nordine T, Créange A, Lefaucheur J-P, Ayache SS. 2018. The ulnar ratio as a sensitive and specific marker of acute inflammatory demyelinating polyneuropathy. *Clinical Neurophysiology* 129(8):1699–1703 DOI 10.1016/j.clinph.2018.05.017.
- Al-Shekhlee A, Robinson J, Katirji B. 2007. Sensory sparing patterns and the sensory ratio in acute inflammatory demyelinating polyneuropathy. *Muscle & Nerve* 35(2):246–250 DOI 10.1002/mus.20660.
- Areeyapinan P, Phanthumchinda K. 2010. Guillain-Barré syndrome: a clinical study in King Chulalongkorn Memorial Hospital. *Journal of the Medical Association of Thailand* 93(10):1150–1155.
- Derksen A, Ritter C, Athar P, Kieseier BC, Mancias P, Hartung HP, Sheikh KA, Lehmann HC. 2014. Sural sparing pattern discriminates guillain-Barré syndrome from its mimics. *Muscle & Nerve* 50(5):780–784 DOI 10.1002/mus.24226.
- Doets AY, Verboon C, Van den Berg B, Harbo T, Cornblath DR, Willison HJ, Islam Z, Attarian S, Barroso FA, Bateman K, Benedetti L, Van den Bergh P, Casasnovas C, Cavaletti G, Chavada G, Claeys KG, Dardiotis E, Davidson A, Van Doorn PA, Feasby TE, Galassi G, Gorson KC, Hartung H-P, Hsieh S-T, Hughes RAC, Illa I, Islam B, Kusunoki S, Kuwabara S, Lehmann HC, Miller JAL, Mohammad QD, Monges S, Nobile Orazio E, Pardo J, Pereon Y, Rinaldi S, Querol L, Reddel SW, Reisin RC, Shahrizaila Nortina, Sindrup SH, Waqar W, Jacobs BC, IGOS Consortium. 2018. Regional variation of Guillain-Barré syndrome. *Brain* 141:2866–2877 DOI 10.1093/brain/awy232.
- Durand MC, Porcher R, Orlikowski D, Aboab J, Devaux C, Clair B, Annane D, Gaillard J-L, Lofaso F, Raphael J-C, Sharshar Tarek. 2006. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study. *Lancet Neurology* 5(12):1021–1028 DOI 10.1016/S1474-4422(06)70603-2.
- **Gómez-Piña JJ, Cabib C, Estañol B, Chiquete E. 2021.** Preservation of sural nerve in classic forms of Guillain-Barré in a Mexican health institution. *Revista Mexicana De Neurociencia* **22**(1):10–14.
- Green C, Baker T, Subramaniam A. 2018. Predictors of respiratory failure in patients with Guillain-Barré syndrome: a systematic review and meta-analysis. *Medical Journal of Australia* 208(4):181 DOI 10.5694/mja17.00552.

- Gupta D, Deepak G, Nair M, Muraleedharan N, Baheti NN, Sarma PS, Abraham
 K. 2008. Electrodiagnostic and clinical aspects of Guillain-Barré syndrome: an analysis of 142 cases. *Journal of Clinical Neuromuscular Disease* 10(2):42–51
 DOI 10.1097/CND.0b013e31818e9510.
- Hughes RAC, Cornblath DR. 2005. Guillain-Barré syndrome. *Lancet* 366(9497):1653–1666 DOI 10.1016/S0140-6736(05)67665-9.
- Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. 1978. Controlled trial prednisolone in acute polyneuropathy. *Lancet* 2(8093):750–753.
- Islam Z, Papri N, Ara G, Ishaque T, Alam AU, Jahan I, Islam B, Mohammad QD. 2019. Risk factors for respiratory failure in Guillain-Barré syndrome in Bangladesh: a prospective study. *Annals of Clinical and Translational Neurology* **6**(2):324–332 DOI 10.1002/acn3.706.
- Kanikannan MAK, Durga P, Venigalla NK, Kandadai RM, Jabeen SA, Borgohain R. 2014. Simple bedside predictors of mechanical ventilation in patients with Guillain-Barré syndrome. *Journal of Critical Care* 29(2):219–223 DOI 10.1016/j.jcrc.2013.10.026.
- Kasemsap N, Vorasoot N, Kongbunkiat K, Tiamkao S, Chotmongkol V, Sawanyawisuth K, Panitchote A. 2021. The epidemiology of Guillain-Barré syndrome in Thailand over 13 years (2005-2017): a nationwide population-based retrospective cohort study. *Journal of the Peripheral Nervous System* 26(2):202–208 DOI 10.1111/jns.12453.
- Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. 2001. Anticipating mechanical ventilation in Guillain-Barré syndrome. *Archives of Neurology* 58(6):893–898 DOI 10.1001/archneur.58.6.893.
- Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, van Doorn PA, Dourado ME, Hughes RAC, Islam B, Kusunoki S, Pardo CA, Reisin R, Sejvar JJ, Shahrizaila N, Soares C, Umapathi T, Wang Y, Yiu EM, Willison HJ, Jacobs BC. 2019. Diagnosis and management of Guillain-Barré syndrome in ten steps. *Nature Reviews Neurology* 15(11):671–683.
- Luo HY, Hong SQ, Li M, Wang L, Jiang L. 2020. Risk factors for mechanical ventilation in children with Guillain-Barré syndrome. *Muscle & Nerve* 62(2):214–218 DOI 10.1002/mus.26905.
- Malaga M, Rodriguez-Calienes A, Marquez-Nakamatsu A, Recuay K, Merzthal L, Bustamante-Paytan D, Sifuentes JM, Castillo-Kohatsu G, Alva-Diaz C. 2021. Predicting mechanical ventilation using the EGRIS in Guillain-Barré syndrome in a latin American Country. *Neurocritical Care* 35(3):775–782 DOI 10.1007/s12028-021-01218-z.
- Mani AM, Prabhakar AT, Alexander PT, Nair A, Vijayaraghavan A, Shaikh A, et al. 2021. Utility of serial nerve conduction studies in the electrodiagnosis of Guillain-Barré Syndrome. *Neurology India* 69(2):369–375 DOI 10.4103/0028-3886.314529.
- McGrogan A, Madle GC, Seaman HE, De Vries CS. 2009. The epidemiology of Guillain-Barré syndrome worldwide a systematic literature review. *Neuroepidemiology* 32(2):150–163 DOI 10.1159/000184748.

- Ning PP, Yang BY, Yang XL, Zhao QZ, Huang HY, Shen QY, Lu H, Tian S, Xu Y. 2020. A nomogram to predict mechanical ventilation in Guillain-Barré syndrome patients. *Acta Neurologica Scandinavica* 142(5):466–474 DOI 10.1111/ane.13294.
- Parveen A, Khan SA, Talat S, Hussain SNF. 2020. Comparison of the clinical outcomes of Guillain Barré syndrome based on electrophysiological subtypes in Pakistani children. *Cureus* 12(5):e8052 DOI 10.7759/cureus.8052.
- Rajabally YA, Dur MC, Mitchell J, Orlikowski D, Nicolas G. 2015. Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice? *Journal of Neurology, Neurosurgery and Psychiatry* 86(1):115–119 DOI 10.1136/jnnp-2014-307815.
- Rantala H, Uhari M, Cherry JD, Shields WD. 1995. Risk factors of respiratory failure in children with Guillain-Barré syndrome. *Pediatric Neurology* 13(4):289–292 DOI 10.1016/0887-8994(95)00189-1.
- Rasera A, Romito S, Segatti A, Concon E, Alessandrini L, Basaldella F, Badari A,
 Bonetti B, Squintani G. 2021. Very early and early neurophysiological abnormalities in Guillain-Barré syndrome: a 4-year retrospective study. *European Journal of Neurology* 28(11):3768–3773 DOI 10.1111/ene.15011.
- Sejvar JJ, Baughman AL, Wise M, Morgan OW. 2011. Population incidence of Guillain-Barré Syndrome: a systematic review and meta-analysis. *Neuroepidemiology* 36(2):123–133 DOI 10.1159/000324710.
- Shangab M, Al Kaylani M. 2021. Clinical predictors for mechanical ventilation and prognosis in patients with Guillian-Barré syndrome: a 10-year experience. *Neurological Sciences* 42(12):5305–5309 DOI 10.1007/s10072-021-05251-w.
- Sharma CM, Pandey RK, Kumawat BL, Khandelwal D, Acharya M. 2016. Guillain-Barré syndrome in north-western India: demographic, clinical, electrophysiological profile and assessment of prognostic factors. *Indian Journal of Medical Specialities* 7(3):109–115 DOI 10.1016/j.injms.2016.06.003.
- Sharshar T, Chevret S, Bourdain F, Raphaël JC, Syndrome FCGoPEiG-B. 2003. Early predictors of mechanical ventilation in Guillain-Barré syndrome. *Critical Care Medicine* 31(1):278–283 DOI 10.1097/00003246-200301000-00044.
- Sudulagunta S, Sodalagunta M, Sepehrar M, Khorram H, Raja S, Kothandapani S, Noroozpour Z, Sham MA, Prasad N, Sunny SP, Mohammed MD, Gangadharappa R, Sudarshan RN. 2015. Guillain-Barré syndrome: clinical profile and management. GMS German Medical Science 13:1–15 DOI 10.3205/000220.
- Sundar U, Abraham E, Gharat A, Yeolekar ME, Trivedi T, Dwivedi N. 2005. Neuromuscular respiratory failure in Guillain-Barré Syndrome: evaluation of clinical and electrodiagnostic predictors. *Journal of the Association of Physicians of India* 53:764–768.
- Toamad U, Kongkamol C, Setthawatcharawanich S, Limapichat K, Phabphal K, Sathirapanya P. 2015. Clinical presentations as predictors of prolonged mechanical ventilation in Guillain-Barré syndrome in an institution with limited medical resources. *Singapore Medical Journal* 56(10):558–561 DOI 10.11622/smedj.2015152.

- Umapathi T, Li ZB, Verma K, Yuki N. 2015. Sural-sparing is seen in axonal as well as demyelinating forms of Guillain-Barré syndrome. *Clinical Neurophysiology* 126(12):2376–2380 DOI 10.1016/j.clinph.2015.01.016.
- **Umer SR, Nisa Q, Kumari M, Abbas S, Mahesar SA, Shahbaz NN. 2019.** Clinical features indicating the need for mechanical ventilation in patients with guillain Barré syndrome. *Cureus* **11(8)**:e5520 DOI 10.7759/cureus.5520.
- Uncini A, Ippoliti L, Shahrizaila N, Sekiguchi Y, Kuwabara S. 2017. Optimizing the electrodiagnostic accuracy in Guillain-Barré syndrome subtypes: criteria sets and sparse linear discriminant analysis. *Clinical Neurophysiology* **128**(7):1176–1183 DOI 10.1016/j.clinph.2017.03.048.
- Uncini A, Kuwabara S. 2018. The electrodiagnosis of Guillain-Barré syndrome subtypes: where do we stand? *Clinical Neurophysiology* **129(12)**:2586–2593 DOI 10.1016/j.clinph.2018.09.025.
- Verma R, Chaudhari TS, Raut TP, Garg RK. 2013. Clinico-electrophysiological profile and predictors of functional outcome in Guillain-Barré syndrome (GBS). *Journal of the Neurological Sciences* 335(1-2):105–111 DOI 10.1016/j.jns.2013.09.002.
- Walgaard C, Lingsma HF, Ruts L, Drenthen J, Van Koningsveld R, Garssen MJP, van Doorn PA, Steyerberg EW, Jacobs BC. 2010. Prediction of respiratory insufficiency in Guillain-Barré syndrome. *Annals of Neurology* 67(6):781–787 DOI 10.1002/ana.21976.
- Wen PY, Wang LS, Liu H, Gong L, Ji H, Wu HL, et al. 2021. Risk factors for the severity of Guillain-Barré syndrome and predictors of short-term prognosis of severe Guillain-Barré syndrome. *Scientific Reports* 11(1):11578 DOI 10.1038/s41598-021-91132-3.
- Wu X, Li C, Zhang B, Shen D, Li T, Liu K, Zhang H-L. 2015. Predictors for mechanical ventilation and short-term prognosis in patients with Guillain-Barré syndrome. *Critical Care* 19:310 DOI 10.1186/s13054-015-1037-z.
- Yadegari S, Nafissi S, Kazemi N. 2014. Comparison of electrophysiological findings in axonal and demyelinating Guillain-Barré syndrome. *Iranian Journal of Neurology* 13(3):138–143.
- Yamagishi Y, Suzuki H, Sonoo M, Kuwabara S, Yokota T, Nomura K, Chiba A, Kaji R, Kanda T, Kaida K, Ikeda S-i, Mutoh T, Yamasaki R, Takashima H, Matsui M, Nishiyama K, Sobue G, Kusunoki S. 2017. Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study. *Journal of the Peripheral Nervous System* 22(4):433–439 DOI 10.1111/jns.12234.
- Ye YQ, Zhu D, Wang KR, Wu JA, Feng JC, Ma DH, Xing Y, Jiang X. 2010. Clinical and electrophysiological features of the 2007 Guillain-Barré syndrome epidemic in northeast China. *Muscle & Nerve* 42(3):311–314 DOI 10.1002/mus.21701.